Results 181 to 190 of about 6,429,838 (267)

Immune Response Gene Polymorphisms and Cervical Cancer Susceptibility. [PDF]

Int J Mol Sci
Dwornik R, Cylwik D, Białkowska K.
europepmc   +1 more source

Single‐molecule DNA flow‐stretch assays for high‐throughput DNA–protein interaction studies

FEBS Open Bio, EarlyView.
We describe an optimised single‐molecule DNA flow‐stretch assay that visualises DNA–protein interactions in real time. Linear DNA fragments are tethered to a surface and stretched by buffer flow for fluorescence imaging. Using λ and φX174 DNA, this protocol enhances reproducibility and accessibility, providing a versatile approach for studying diverse ...
Ayush Kumar Ganguli, Mohammad Nour Alsamsam, Ugnė Bagdonaitė, Van Truc Vu, Chun‐Jen Huang, Polina Kuzhir, Mindaugas Zaremba, Aurimas Kopūstas, Marijonas Tutkus   +8 more
wiley   +1 more source

Local treatment vs. years of life lost in intermediate-risk prostate cancer. [PDF]

World J Urol
Falkenbach F, Longoni M, Marmiroli A, Le QC, Catanzaro C, Nicolazzini M, Polverino F, Goyal JA, Schiavina R, Palumbo C, Musi G, Chun FKH, Briganti A, Saad F, Shariat SF, Budäus L, Graefen M, Karakiewicz PI.   +17 more
europepmc   +1 more source

Transcripts enriched in codons that trigger P‐site tRNA‐mediated mRNA decay possess stable mRNA

FEBS Open Bio, EarlyView.
PTMD codons were first described by Mendel et al. as mediators of an mRNA decay pathway dependent on the human protein CNOT3, homologous to yeast Not5. Our findings confirm that PTMD codons destabilize transcripts; however, unlike in yeast, the human pathway specifically targets and slightly destabilizes primarily stable mRNAs.
Rodolfo Lopes Carneiro, Fernando Lucas Palhano   +1 more
wiley   +1 more source

Cardiovascular Risk of Conventional Synthetic, Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Common Rheumatic Diseases: A Narrative Review of Current Evidence. [PDF]

Ther Clin Risk Manag
Nian F, Chen Z, Qian Y, Yang M, Zhang B.
europepmc   +1 more source

Treatment with KCL‐286, a first‐in‐class retinoic acid receptor‐β (RARβ) agonist, ameliorates neuronal DNA damage and inflammation in a mouse model of Alzheimer's disease

FEBS Open Bio, EarlyView.
Repair of neuronal DNA damage in Alzheimer's disease by KCL‐286. (A) Amyloid‐β oligomers and plaques impair neuronal DNA repair pathways, leading to DNA double‐strand breaks and glial activation. (B) KCL‐286 activates RARβ/RXR signalling via retinoic acid response elements (RAREs), associated with increased BRCA1 expression, enhanced DNA repair and ...
Natasha Hill, Hassan Yousef Othman AlMuallim, Elouisa Maddock, Carl Hobbs, Earl Clarke, Maria B. Goncalves, Jonathan P. T. Corcoran   +6 more
wiley   +1 more source

Vitamin D Supplementation and Mortality in the Elderly: A Review of a Meta-Analysis of Randomized Controlled Trials Using the REB Method. [PDF]

Fundam Clin Pharmacol
Kostakis N, Lega JC, Boussageon R.
europepmc   +1 more source

Pathways and pitfalls: a qualitative study of student experiences in biomedical science education

FEBS Open Bio, EarlyView.
Biomedical science students from underrepresented backgrounds face barriers including financial strain, disrupted laboratory access and cultural exclusion. Peer networks provide vital support when institutional systems are difficult to navigate. To create inclusive learning environments and achieve academic success, educators should blend active, hands‐
Olivia J. Russell, Cassy Ross, Panagiota S. Filippou, Bruno Silvester Lopes, Dominic Gilchrist, Paul Dean, Kamar Ameen‐Ali, Tora K. Smulders‐Srinivasan, Ahmad A. Khundakar   +8 more
wiley   +1 more source

Anticipating Surprises by Expanding a Risk Assessment's Possibility Space Into the Unknown With C-K Theory. [PDF]

Risk Anal
Derbyshire J.
europepmc   +1 more source